Abstract: Anti-angiogenic treatments, treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, pain treatments, methods of reducing the risk of pre-eclampsia and compounds for use in such methods are described.

Abstract: The present invention relates to a production process of a 4-hydroxy-benzoic acid long chain ester, that includes a step of reacting a 4-hydroxy-benzoic acid short chain ester with an aliphatic alcohol in the presence of a metal catalyst. The present invention also relates to a purification process of a 4-hydroxy-benzoic acid long chain ester, that includes a step of adding an acid aqueous solution to a crude composition including the 4-hydroxy-benzoic acid long chain ester, separating the crude composition to an organic phase and a water phase and extracting the organic phase.

Abstract: A process for removing acetaldehyde efficiently and producing high-purity acetic acid stably is provided. Methanol is allowed to continuously react with carbon monoxide in a carbonylation reactor 1 in the presence of a catalyst system; the reaction mixture is continuously fed to a flasher 2 to form a volatile phase (2A) containing acetic acid and methyl iodide; the volatile phase (2A) is continuously fed to a splitter column 3 to form an overhead (3A) containing methyl iodide and acetaldehyde and a stream (3B) containing acetic acid; the volatile phase (2A) and/or the overhead (3A) is cooled by a first condenser C1, C3 at a predetermined cooling temperature; and the noncondensed gaseous component is further cooled by a second condenser C2, C4 to form a concentrate having a lower temperature and a higher acetaldehyde concentration. Acetaldehyde is efficiently removed by distilling the concentrate having a high acetaldehyde concentration.

Abstract: The invention relates to a method for producing carboxylic acid esters by reacting carboxylic acids and/or carboxylic acid anhydrides with at least one alcohol having at least 5 carbon atoms, selected from alkanols and cycloalkanols, in the presence of an ionic liquid and an acidic esterification catalyst. The invention also relates to the use of the thus obtained carboxylic acid esters as a plasticizer or in a plasticizer composition for thermoplastic polymers and elastomers.

Abstract: The present application relates to a sulfonate-based compound and a method for preparing the same.

Abstract: Embodiments of the present disclosure provide for compositions including an antimicrobial agent, pharmaceutical compositions including the composition or pharmaceutical composition, methods of treating a condition or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.

Abstract: A cosmetic composition suitable for topical application is provided. The cosmetic composition comprises: a safe and effective amount of a humectant; a safe and effective amount of a lipid bilayer structurant, and a safe and effective amount of a chaotropic agent. The chaotropic agent denatures the cross-linked proteinaceous layer sitting immediately above skin thereby increasing the amount of humectant and lipid bilayer structurant that enters the stratum corneum; the humectant binds together with water molecules and the lipid bilayer structurant knits together the lipid bilayers of the stratum corneum thereby preventing water loss.

Abstract: A pharmaceutical composition is provided which includes perillyl alcohol conjugated with a therapeutic agent and further includes and a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer.

Abstract: An object to be achieved by the present invention is to provide a novel compound having EGFR inhibitory effects and cell growth inhibitory effects, as well as a medication useful for the prevention and/or treatment of cancer based on the EGFR inhibitory effects. The present invention provides a compound represented by Formula (I) below, or a salt thereof.

Abstract: The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.

Abstract: Object: An object of the present invention is to provide a method for producing, with a high yield, a fluorinated organic compound, the fluorinated organic compound having not been produced with a sufficient yield by a conventional method for producing a fluorinated organic compound using a fluorinating agent containing IF5-pyridine-HF alone. Another object of the present invention is to provide a fluorinating reagent. Means for achieving the object: A method for producing a fluorinated organic compound comprising step A of fluorinating an organic compound by bringing the organic compound into contact with (1) IF5-pyridine-HF and (2) at least one additive selected from the group consisting of amine hydrogen fluorides, XaF (wherein Xa represents hydrogen, potassium, sodium, or lithium), oxidizers, and reducing agents.

Abstract: The present invention is directed to a method of treating inflammation or pain. The present invention is also directed to a method of treating an inflammatory skin disease or disorder, such as dermatitis, psoriasis, acne, or rosacea. The method comprises administering to the subject 3, 4-bis-benzylsulfonylbutyronitrile in an amount effective to reduce or eliminate the symptoms of the disease or disorder. Topical administration and oral administration are preferred route of administration.

Abstract: The present invention relates to a process to crystallize a chelating agent containing a step of adding seeds to a saturated or supersaturated aqueous solution or dispersion of the chelating agent and a subsequent step of milling the dispersion, wherein the step of milling the dispersion is performed using equipment operating at at least 1,000 rpm, and to products obtainable by such process.

Abstract: The present invention relates to using a two-step (thermolysis) or one-pot process to prepare aliphatic diisocyanates from aliphatic diamines and diaryl carbonates. Polyisocyanates can also be prepared from polyamines and diaryl carbonates. The present synthetic processes do not apply phosgene or highly toxic reagents and chloro-solvents during the entire procedure.

Abstract: Compositions useful for making dosage forms capable of dissolving or disintegrating in less than 10 seconds without the need for conventional disintegrants and methods making and using the same are disclosed.

Abstract: Described herein is a process for preparing urethane (meth)acrylates. In a first step, a hydroxyalkyl (meth)acrylate is reacted with a lactone (B) in the presence of at least one zinc compound and/or bismuth compound (C) to produce a resulting zinc-containing product and/or a bismuth-containing product, and, in a further step, the zinc-containing product and/or the bismuth-containing product is reacted with at least one cycloaliphatic or asymmetric aliphatic diisocyanate (D).

Abstract: Presented herein are methods for treatment of diseases or conditions related to fibrosis. Compounds, or pharmaceutically acceptable salts thereof or pharmaceutical compositions thereof provide for the treatment of diseases or conditions related to fibrosis.

Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.

Abstract: The present disclosures and inventions relate to methods for the preparation of acetic acid via the oxidation of ethane, including the preparation of high purity acetic acid that comprises very low concentrations of formic acid impurity. More specifically, described herein are methods for producing acetic acid comprising: a. producing a crude acetic acid composition comprising formic acid from ethane via ethane oxidation; and then b. purifying the crude acetic acid composition by crystallization to remove formic acid to achieve a purified acetic acid composition; wherein the formic acid is present in the purified acetic acid composition in an amount less than 0.2% by weight, based on the total weight of the purified acetic acid composition.

Abstract: A protected organoboronic acid includes a boron having an sp3 hybridization, a conformationally rigid protecting group bonded to the boron, and an organic group bonded to the boron through a boron-carbon bond. A method of performing a chemical reaction includes contacting a protected organoboronic acid with a reagent, the protected organoboronic acid including a boron having an sp3 hybridization, a conformationally rigid protecting group bonded to the boron, and an organic group bonded to the boron through a boron-carbon bond. The organic group is chemically transformed, and the boron is not chemically transformed.